Level C· Early human research exploring benefitsProspective StudyPubMed

Decellularization of human iliac artery: A vascular scaffold for peripheral repairs with human mesenchymal cells.

Abad-Contreras DE., Martínez-Ortiz AK., Martínez-López V., Laparra-Escareño H., Martínez-García FD., Pérez-Calixto D.

Prospective Study on Peripheral Artery Disease, published in Tissue Cell (2024) — summary generated from the PubMed abstract.

Open my reading list
Level C· Early human research exploring benefitsEvidence level of this study

Early human evidence such as case series or small samples is exploring possible benefits.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Prospective Study
Journal
Tissue Cell (2024)
Country
Scotland
Reported sample size
—
Source database
PubMed
PMID
39724840
DOI
10.1016/j.tice.2024.102686
Citations
2

Abstract (original English)

This work presents strong evidence supporting the use of decellularized human iliac arteries combined with adipose tissue-derived stem cells (hASCs) as a promising alternative for vascular tissue engineering, opening the path to future treatments for peripheral artery disease (PAD). PAD is a progressive condition with high rates of amputation and mortality due to ischemic damage and limited graft options. Traditional synthetic grafts often fail due to poor integration, while autologous grafts may be unsuitable for patients with compromised vascular health. This study explores the potential of decellularized human iliac arteries as scaffolds for vascular grafts, focusing on preserving extracellular matrix (ECM) ultrastructure while minimizing immunogenic response. A perfusion-based protocol with enzymatic and detergent agents effectively removed cellular material, resulting in scaffolds with preserved ECM architecture, including organized collagen and elastin fibers. To assess scaffold bioactivity, hASCs were seeded onto the decellularized ECM, demonstrating high viability. Structural assessments, including histological staining and mechanical testing, confirmed that decellularized arteries retained their hierarchical structure and exhibited increased stiffness, suggesting an adaptive realignment of ECM fibers. Thermal and ultrastructural analyses further showed that decellulari

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.

Evidence level

Early human evidence such as case series or small samples is exploring possible benefits.

How we grade evidence
HumansTissue ScaffoldsIliac ArteryMesenchymal Stem CellsTissue EngineeringExtracellular MatrixDecellularized Extracellular MatrixAdipose Tissue

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research